People with early-stage Huntington's disease were able to safely restrict their eating to a six-to-eight-hour window each day for 12 weeks, and did so without the unintended weight loss that often accompanies the condition, according to a pilot study led by Oregon Health & Science University and published in Nature Metabolism. It is the first clinical study to test time-restricted eating, a form of intermittent fasting, in people with the disease.
Alongside stable weight, participants showed improvements on measures of disease severity, in a blood biomarker tied to nerve cell damage, and in cellular energy production. That combination is notable because it spans what clinicians can observe and what is happening at the biological level, rather than resting on subjective report alone.
Weight loss is a practical concern in Huntington's disease, so the question of whether a fasting-style schedule could be tolerated at all was not a small one. The finding that participants stuck to the schedule and held their weight is arguably as important as the biological signals, since any intervention that compromised nutrition would be a non-starter for this group.
The researchers frame the results as encouraging but preliminary, and say time-restricted eating now warrants testing in a larger clinical trial. A 12-week pilot in people with early-stage disease cannot establish whether the approach slows the course of the illness over years, and that is the question a bigger, longer study would need to answer.